{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:28:04Z","timestamp":1789612084552,"version":"build-2803163510"},"reference-count":131,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cExcellence Initiative\u2014Research University\u201d Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Classical Hodgkin lymphoma (cHL) is a biologically and clinically unique malignancy characterized by rare Hodgkin and Reed\u2013Sternberg (HRS) cells surrounded by a dense and diverse inflammatory infiltrate. These malignant cells actively reshape the tumor microenvironment (TME) through metabolic reprogramming and immune evasion strategies. This review synthesizes current knowledge on how metabolic alterations contribute to tumor survival, immune dysfunction, and therapeutic resistance in cHL. We discuss novel therapeutic approaches aimed at disrupting these processes and examine the potential of combining metabolic interventions with immune-based strategies\u2014such as immune checkpoint inhibitors (CPIs), epigenetic modulators, bispecific antibodies, and CAR-T\/CAR-NK cell therapies\u2014which may help overcome resistance and enhance anti-tumor responses. Several agents are currently under investigation for their ability to modulate immune cell metabolism and restore effective immune surveillance. Altogether, targeting metabolic vulnerabilities within both tumor and immune compartments offers a promising, multifaceted strategy to improve clinical outcomes in patients with relapsed or refractory cHL.<\/jats:p>","DOI":"10.3390\/ijms26157508","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T07:45:11Z","timestamp":1754466311000},"page":"7508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Metabolic Interactions in the Tumor Microenvironment of Classical Hodgkin Lymphoma: Implications for Targeted Therapy"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6134-7425","authenticated-orcid":false,"given":"Micha\u0142","family":"Kurlapski","sequence":"first","affiliation":[{"name":"Department of Hematology and Transplantology, University Clinical Centre, Medical University of Gdansk, 80-211 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4394-0292","authenticated-orcid":false,"given":"Alicja","family":"Braczko","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical University of Gdansk, 80-211 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8537-4404","authenticated-orcid":false,"given":"Pawe\u0142","family":"Dubiela","sequence":"additional","affiliation":[{"name":"Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-269 Bia\u0142ystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iga","family":"Walczak","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical University of Gdansk, 80-211 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Kutryb-Zaj\u0105c","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Medical University of Gdansk, 80-211 Gda\u0144sk, Poland"},{"name":"Centre for Experimental Cardiooncology, Medical University of Gdansk, 80-211 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0986-8936","authenticated-orcid":false,"given":"Jan Maciej","family":"Zaucha","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, University Clinical Centre, Medical University of Gdansk, 80-211 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.15614","article-title":"Diagnosis of Hodgkin Lymphoma in the Modern Era","volume":"184","author":"Wang","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_2","unstructured":"Aggarwal, P., and Limaiem, F. (2025). Reed-Sternberg Cells. Brenner\u2019s Encyclopedia of Genetics, Elsevier Science. [2nd ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1092-9134(03)00020-0","article-title":"Whatever Happened to Dorothy Reed?","volume":"7","author":"Dawson","year":"2003","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular Pathogenesis of Hodgkin\u2019s Lymphoma: Increasing Evidence of the Importance of the Microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Opinto, G., Agostinelli, C., Ciavarella, S., Guarini, A., Maiorano, E., and Ingravallo, G. (2021). Hodgkin Lymphoma: A Special Microenvironment. J. Clin. Med., 10.","DOI":"10.3390\/jcm10204665"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and Reed-Sternberg Cells Represent an Expansion of a Single Clone Originating from a Germinal Center B-Cell with Functional Immunoglobulin Gene Rearrangements but Defective Immunoglobulin Transcription","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood"},{"key":"ref_7","first-page":"1644","article-title":"Typing the Histogenetic Origin of the Tumor Cells of Lymphocyte-Rich Classical Hodgkin\u2019s Lymphoma in Relation to Tumor Cells of Classical and Lymphocyte-Predominance Hodgkin\u2019s Lymphoma 1","volume":"63","author":"Wacker","year":"2003","journal-title":"Cancer Res."},{"key":"ref_8","first-page":"2059","article-title":"The Microenvironmental Niche in Classic Hodgkin Lymphoma Is Enriched for CTLA-4-Positive T Cells That Are PD-1-Negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular Biology of Hodgkin Lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/1-4020-7847-1_8","article-title":"Nuclear Factor-KappaB Activation Mediates Cellular Transformation, Proliferation, Invasion Angiogenesis and Metastasis of Cancer","volume":"119","author":"Shishodia","year":"2004","journal-title":"Cancer Treat. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/hematology.2023000450","article-title":"The Optimal Management of Relapsed and Refractory Hodgkin Lymphoma: Post\u2013Brentuximab and Checkpoint Inhibitor Failure","volume":"2023","author":"Grover","year":"2023","journal-title":"Hematology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101514","DOI":"10.1016\/j.beha.2023.101514","article-title":"Hodgkin Lymphoma: A Disease Shaped by the Tumor Micro- and Macroenvironment","volume":"36","author":"Masel","year":"2023","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Pang, Y., Lu, T., Xu-Monette, Z.Y., and Young, K.H. (2023). Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065493"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","article-title":"Part II: Hodgkin\u2019s Lymphoma\u2014Diagnosis and Treatment","volume":"5","author":"Diehl","year":"2004","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Momotow, J., Borchmann, S., Eichenauer, D.A., Engert, A., and Sasse, S. (2021). Hodgkin Lymphoma-Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10051125"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced Treatment Intensity in Patients with Early-Stage Hodgkin\u2019s Lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bertuzzi, C., Sabattini, E., and Agostinelli, C. (2021). Immune Microenvironment Features and Dynamics in Hodgkin Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13143634"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.canlet.2015.10.007","article-title":"Microenvironmental Interactions in Classical Hodgkin Lymphoma and Their Role in Promoting Tumor Growth, Immune Escape and Drug Resistance","volume":"380","author":"Aldinucci","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The Classical Hodgkin\u2019s Lymphoma Microenvironment and Its Role in Promoting Tumour Growth and Immune Escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2033433","DOI":"10.1080\/2162402X.2022.2033433","article-title":"CD4+ T Cells in Classical Hodgkin Lymphoma Express Exhaustion Associated Transcription Factors TOX and TOX2: Characterizing CD4+ T Cells in Hodgkin Lymphoma","volume":"11","author":"Veldman","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/bloodadvances.2021006189","article-title":"Checkpoint Protein Expression in the Tumor Microenvironment Defines the Outcome of Classical Hodgkin Lymphoma Patients","volume":"6","author":"Karihtala","year":"2022","journal-title":"Blood Adv."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.seminoncol.2010.09.005","article-title":"Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer\u2014Preclinical Background: CTLA-4 and PD-1 Blockade","volume":"37","author":"Weber","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin Lymphoma with Reduced \u03922M\/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1189\/jlb.3MR0315-136R","article-title":"The Role of T Cells in the Microenvironment of Hodgkin Lymphoma","volume":"99","author":"Wein","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1440-1827.1999.00830.x","article-title":"CD95 Ligand Is Expressed in Reed-Sternberg Cells of Hodgkin\u2019s Disease","volume":"49","author":"Sakuma","year":"1999","journal-title":"Pathol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Alibrahim, M.N., Gloghini, A., and Carbone, A. (2025). Immune Deficiency\/Dysregulation-Associated EBV-Positive Classic Hodgkin Lymphoma. Cancers, 17.","DOI":"10.3390\/cancers17091433"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1111\/j.1600-6143.2009.02781.x","article-title":"Activation of The JAK\/STAT Pathway in Epstein Barr Virus+ Associated Post Transplant Lymphoproliferative Disease: Role of Interferon-\u03b3","volume":"9","author":"Vaysberg","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/PAS.0000000000001919","article-title":"Enhanced PD-L1 Expression in LMP1-Positive Cells of Epstein-Barr Virus-Associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-Cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization","volume":"46","author":"Kume","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Georgoulis, V., Papoudou-Bai, A., Makis, A., Kanavaros, P., and Hatzimichael, E. (2023). Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications. Biology, 12.","DOI":"10.20944\/preprints202305.1213.v1"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Aoki, T., Wierzbicki, K., Sun, S., Steidl, C., Giulino-Roth, L., Merli, P., and Chabay, P. (2025). Tumor-Microenvironment and Molecular Biology of Classic Hodgkin Lymphoma in Children, Adolescents, and Young Adults. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1515250"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/bjh.15801","article-title":"Immune Off-Target Effects of Brentuximab Vedotin in Relapsed\/Refractory Hodgkin Lymphoma","volume":"185","author":"Romano","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The Combined Role of Biomarkers and Interim PET Scan in Prediction of Treatment Outcome in Classical Hodgkin\u2019s Lymphoma: A Retrospective, European, Multicentre Cohort Study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does It Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1042\/BST20160094","article-title":"The Warburg Effect: 80 Years On","volume":"44","author":"Potter","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.seminoncol.2017.10.003","article-title":"Hodgkin Lymphoma: A Complex Metabolic Ecosystem with Glycolytic Reprogramming of the Tumor Microenvironment","volume":"44","author":"Mikkilineni","year":"2017","journal-title":"Semin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Barbato, A., Scandura, G., Puglisi, F., Cambria, D., La Spina, E., Palumbo, G.A., Lazzarino, G., Tibullo, D., Di Raimondo, F., and Giallongo, C. (2020). Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.604143"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.semcancer.2016.05.001","article-title":"NF-\u039aB Deregulation in Hodgkin Lymphoma","volume":"39","author":"Weniger","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Albensi, B.C. (2019). What Is Nuclear Factor Kappa B (NF-\u039aB) Doing in and to the Mitochondrion?. Front. Cell Dev. Biol., 7.","DOI":"10.3389\/fcell.2019.00154"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ravi, D., Kritharis, A., and Evens, A.M. (2024). Deciphering the Metabolic Basis and Molecular Circuitry of the Warburg Paradox in Lymphoma. Cancers, 16.","DOI":"10.3390\/cancers16213606"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1021\/acsptsci.3c00301","article-title":"Inversion of the Warburg Effect: Unraveling the Metabolic Nexus between Obesity and Cancer","volume":"7","author":"Akter","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zhao, Z., Mei, Y., Wang, Z., and He, W. (2023). The Effect of Oxidative Phosphorylation on Cancer Drug Resistance. Cancers, 15.","DOI":"10.3390\/cancers15010062"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.cmet.2022.09.023","article-title":"The Role of Lipids in Cancer Progression and Metastasis","volume":"34","author":"Bigas","year":"2022","journal-title":"Cell Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1073\/pnas.1008969108","article-title":"Critical Role of PI3K Signaling for NF-\u039aB-Dependent Survival in a Subset of Activated B-Cell-like Diffuse Large B-Cell Lymphoma Cells","volume":"108","author":"Kloo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood.2020005602","article-title":"Increased Lipid Metabolism Impairs NK Cell Function and Mediates Adaptation to the Lymphoma Environment","volume":"136","author":"Kobayashi","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","article-title":"Lipid Metabolism in Cancer: New Perspectives and Emerging Mechanisms","volume":"56","author":"Broadfield","year":"2021","journal-title":"Dev. Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/imcb.12557","article-title":"Amino Acid Metabolism: Challenges and Opportunities for the Therapeutic Treatment of Leukemia and Lymphoma","volume":"100","author":"Liao","year":"2022","journal-title":"Immunol. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wang, M., Zhao, A., Li, M., and Niu, T. (2023). Amino Acids in Hematologic Malignancies: Current Status and Future Perspective. Front. Nutr., 10.","DOI":"10.3389\/fnut.2023.1113228"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/01.HS9.0000848016.80736.c9","article-title":"P1288: Altered Amino Acid Homeostasis Can Elicit an Adaptive Response Via Upregulation of Ufmylation in Hodgkin Lymphoma","volume":"6","author":"Romano","year":"2022","journal-title":"Hemasphere"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Barberini, L., Noto, A., Fattuoni, C., Satta, G., Zucca, M., Cabras, M.G., Mura, E., and Cocco, P. (2019). The Metabolomic Profile of Lymphoma Subtypes: A Pilot Study. Molecules, 24.","DOI":"10.3390\/molecules24132367"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Cabrera-Serrano, A.J., S\u00e1nchez-Maldonado, J.M., Gonz\u00e1lez-Olmedo, C., Carretero-Fern\u00e1ndez, M., D\u00edaz-Beltr\u00e1n, L., Guti\u00e9rrez-Bautista, J.F., Garc\u00eda-Verdejo, F.J., G\u00e1lvez-Montosa, F., L\u00f3pez-L\u00f3pez, J.A., and Garc\u00eda-Mart\u00edn, P. (2025). Crosstalk Between Autophagy and Oxidative Stress in Hematological Malignancies: Mechanisms, Implications, and Therapeutic Potential. Antioxidants, 14.","DOI":"10.20944\/preprints202501.0031.v1"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/his.12389","article-title":"Oxidative Stress Markers and Mitochondrial Antioxidant Enzyme Expression Are Increased in Aggressive Hodgkin Lymphomas","volume":"65","author":"Bur","year":"2014","journal-title":"Histopathology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Marini, C., Cossu, V., Lanfranchi, F., Carta, S., Vitale, F., D\u2019Amico, F., Bauckneht, M., Morbelli, S., Donegani, M.I., and Chiola, S. (2023). Divergent Oxidative Stress in Normal Tissues and Inflammatory Cells in Hodgkin and Non-Hodgkin Lymphoma. Cancers, 15.","DOI":"10.3390\/cancers15133533"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sousa-Pimenta, M., Estevinho, M.M., Sousa Dias, M., Martins, \u00c2., and Estevinho, L.M. (2023). Oxidative Stress and Inflammation in B-Cell Lymphomas. Antioxidants, 12.","DOI":"10.3390\/antiox12040936"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3324\/haematol.2015.127498","article-title":"Potential Role of Hypoxia in Early Stages of Hodgkin Lymphoma Pathogenesis","volume":"100","author":"Wein","year":"2015","journal-title":"Haematologica"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wei, J., Hu, M., and Du, H. (2022). Improving Cancer Immunotherapy: Exploring and Targeting Metabolism in Hypoxia Microenvironment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.845923"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Chen, G., Wu, K., Li, H., Xia, D., and He, T. (2022). Role of Hypoxia in the Tumor Microenvironment and Targeted Therapy. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.961637"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/mco2.6","article-title":"Metabolism in Tumor Microenvironment: Implications for Cancer Immunotherapy","volume":"1","author":"Shi","year":"2020","journal-title":"MedComm"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin Lymphoma","volume":"122","author":"Engert","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V97.9.2798","article-title":"Constitutive NF-\u039aB Maintains High Expression of a Characteristic Gene Network, Including CD40, CD86, and a Set of Antiapoptotic Genes in Hodgkin\/Reed-Sternberg Cells","volume":"97","author":"Hinz","year":"2001","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1042\/BJ20040620","article-title":"Hypoxia-Inducible Factor-1 (HIF-1) Promotes Its Degradation by Induction of HIF-\u03b1-Prolyl-4-Hydroxylases","volume":"381","author":"Marxsen","year":"2004","journal-title":"Biochem. J."},{"key":"ref_62","first-page":"e63852","article-title":"Hypoxia-Inducible Factor 1-Alpha (HIF-1\u03b1): An Essential Regulator in Cellular Metabolic Control","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Paraskeva, E., Haj Zen, A., Zuheir Bakleh, M., and Al Haj Zen, A. (2025). The Distinct Role of HIF-1\u03b1 and HIF-2\u03b1 in Hypoxia and Angiogenesis. Cells, 14.","DOI":"10.3390\/cells14090673"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1113\/JP280572","article-title":"Regulation of Glycolysis by the Hypoxia-Inducible Factor (HIF): Implications for Cellular Physiology","volume":"599","author":"Kierans","year":"2021","journal-title":"J. Physiol."},{"key":"ref_65","first-page":"51","article-title":"Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway and Its Potential for Therapeutic Intervention in Malignancy and Ischemia","volume":"80","author":"Ziello","year":"2007","journal-title":"Yale J. Biol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"102043","DOI":"10.1016\/j.ctrv.2020.102043","article-title":"The Role of Autophagy in Resistance to Targeted Therapies","volume":"88","author":"Mele","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1158\/0008-5472.CAN-11-3831","article-title":"Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Anti-Angiogenic Treatment in Glioblastoma","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"109951","DOI":"10.1016\/j.radonc.2023.109951","article-title":"The Role of Autophagy in Hypoxia-Induced Radioresistance","volume":"189","author":"Hill","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Baldi, A., and Jalouli, M. (2025). Emerging Role of Hypoxia-Inducible Factors (HIFs) in Modulating Autophagy: Perspectives on Cancer Therapy. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041752"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"541","DOI":"10.4161\/cbt.2.5.543","article-title":"Resistance of Follicular Lymphoma Cells to Chemotherapy Is More than Just BCL-2","volume":"2","author":"Hersey","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CCO.0b013e32832f57ec","article-title":"Targeting the Warburg Effect in Hematological Malignancies: From PET to Therapy","volume":"21","author":"Shanmugam","year":"2009","journal-title":"Curr. Opin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/MTOR Signaling Transduction Pathway and Targeted Therapies in Cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_73","unstructured":"(2003). 2-Deoxy-d-Glucose-Induced Cytotoxicity and Radiosensitization in Tumor Cells Is Mediated via Disruptions in Thiol Metabolism. Cancer Res., 63, 3413\u20133417. Available online: https:\/\/aacrjournals.org\/cancerres\/article\/63\/12\/3413\/510064\/2-Deoxy-d-Glucose-induced-Cytotoxicity-and."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.18632\/oncotarget.6315","article-title":"Reversal of the Glycolytic Phenotype of Primary Effusion Lymphoma Cells by Combined Targeting of Cellular Metabolism and PI3K\/Akt\/ MTOR Signaling","volume":"7","author":"Mediani","year":"2015","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Gu, X.Y., Yang, J.L., Lai, R., Zhou, Z.J., Tang, D., Hu, L., and Zhao, L.J. (2025). Impact of Lactate on Immune Cell Function in the Tumor Microenvironment: Mechanisms and Therapeutic Perspectives. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1563303"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"176952","DOI":"10.1016\/j.ejphar.2024.176952","article-title":"The Efficacy and Safety of PI3K and AKT Inhibitors for Patients with Cancer: A Systematic Review and Network Meta-Analysis","volume":"983","author":"Zhang","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1172\/JCI69589","article-title":"Inhibiting Glycolytic Metabolism Enhances CD8+ T Cell Memory and Antitumor Function","volume":"123","author":"Sukumar","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"de-Brito, N.M., Duncan-Moretti, J., da-Costa, H.C., Saldanha-Gama, R., Paula-Neto, H.A., Dorighello, G.G., Sim\u00f5es, R.L., and Barja-Fidalgo, C. (2020). Aerobic Glycolysis Is a Metabolic Requirement to Maintain the M2-like Polarization of Tumor-Associated Macrophages. Biochim. Biophys. Acta Mol. Cell Res., 1867.","DOI":"10.1016\/j.bbamcr.2019.118604"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1078-0432.CCR-18-0706","article-title":"Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-Cell Response","volume":"25","author":"Chatterjee","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in Patients with Classical Hodgkin Lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"175552","DOI":"10.1016\/j.ejphar.2023.175552","article-title":"Characterization of the Effect of the GLUT-1 Inhibitor BAY-876 on T Cells and Macrophages","volume":"945","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1038\/s41467-020-18020-8","article-title":"GLUT1 Inhibition Blocks Growth of RB1-Positive Triple Negative Breast Cancer","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1172\/JCI69741","article-title":"Targeting Lactate Metabolism for Cancer Therapeutics","volume":"123","author":"Doherty","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Lou, J., Tian, Y., Ding, J., Wang, X., and Tang, B. (2024). How Lactate Affects Immune Strategies in Lymphoma. Front. Mol. Biosci., 11.","DOI":"10.3389\/fmolb.2024.1480884"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"14276","DOI":"10.1021\/acs.jmedchem.0c01013","article-title":"Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?","volume":"63","author":"Xu","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood.V122.21.1665.1665","article-title":"The Combination Of 2-DG and Metformin Inhibits The MTORC1 Pathway and Suppresses Aggressive B Cell Lymphoma Growth and Survival","volume":"122","author":"Bi","year":"2013","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Wang, M., Wang, K., Liao, X., Hu, H., Chen, L., Meng, L., Gao, W., and Li, Q. (2021). Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy?. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.760581"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41389-023-00460-8","article-title":"Involvement of the Pro-Oncogenic Enzyme Fatty Acid Synthase in the Hallmarks of Cancer: A Promising Target in Anti-Cancer Therapies","volume":"12","author":"Vanauberg","year":"2023","journal-title":"Oncogenesis"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e39782","DOI":"10.1097\/MD.0000000000039782","article-title":"Metabolomics for Hematologic Malignancies: Advances and Perspective","volume":"103","author":"Li","year":"2024","journal-title":"Medicine"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Wang, Z., Liu, F., Fan, N., Zhou, C., Li, D., Macvicar, T., Dong, Q., Bruns, C.J., and Zhao, Y. (2020). Targeting Glutaminolysis: New Perspectives to Understand Cancer Development and Novel Strategies for Potential Target Therapies. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.589508"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ara, A., Xu, A., Ahmed, K.A., Leary, S.C., Islam, M.F., Wu, Z., Chibbar, R., and Xiang, J. (2021). The Energy Sensor AMPK\u03b11 Is Critical in Rapamycin-Inhibition of MTORC1-S6K-Induced T-Cell Memory. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010037"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.4049\/jimmunol.1901213","article-title":"Metformin Enhances the Antitumor Activity of CD8+ T Lymphocytes via the AMPK-MiR-107-Eomes-PD-1 Pathway","volume":"204","author":"Zhang","year":"2020","journal-title":"J. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e009245","DOI":"10.1136\/jitc-2024-009245","article-title":"Blocking the CD39\/CD73 Pathway Synergizes with Anti-CD20 Bispecific Antibody in Nodal B-Cell Lymphoma","volume":"13","author":"Kolbe","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/bjh.18762","article-title":"Low B-Cell Content Is Associated with a CD73-Low Tumour Microenvironment and Unfavourable Prognosis in Classic Hodgkin Lymphoma","volume":"201","author":"Grund","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors in Cancer Therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","article-title":"SHR2554, an EZH2 Inhibitor, in Relapsed or Refractory Mature Lymphoid Neoplasms: A First-in-Human, Dose-Escalation, Dose-Expansion, and Clinical Expansion Phase 1 Trial","volume":"9","author":"Song","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood-2023-190753","article-title":"The Combination of Nivolumab and CC-486 Is Active in Hodgkin Lymphoma Refractory to PD-1 Blockade","volume":"142","author":"Mei","year":"2023","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Vassilakopoulos, T.P., Liaskas, A., Pereyra, P., Panayiotidis, P., Angelopoulou, M.K., and Gallamini, A. (2023). Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713187"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/ajh.25154","article-title":"Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Failed Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Series from Lysa Centers","volume":"93","author":"Rossi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00262-024-03735-0","article-title":"Inhibition of Glycolysis Enhances the Efficacy of Immunotherapy via PDK-Mediated Upregulation of PD-L1","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eade8520","DOI":"10.1126\/science.ade8520","article-title":"JAK Inhibition Enhances Checkpoint Blockade Immunotherapy in Patients with Hodgkin Lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V128.22.183.183","article-title":"A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039)","volume":"128","author":"Ansell","year":"2016","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for Patients with Relapse after Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_107","unstructured":"Study Details (2025, July 23). Ipilimumab With or Without Nivolumab in Relapsed\/Refractory CHL. ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04938232."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2021-151728","article-title":"Safety and Efficacy of Vibostolimab and Pembrolizumab in Patients with Relapsed or Refractory Hematologic Malignancies: A Multicohort, Open-Label, Phase 2 Study","volume":"138","author":"Yusuf","year":"2021","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.1182\/blood-2023-182019","article-title":"Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1\/2 Study","volume":"142","author":"Timmerman","year":"2023","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s12672-024-01210-x","article-title":"CCL17, CCL22 and Their Receptor CCR4 in Hematologic Malignancies","volume":"15","author":"Zou","year":"2024","journal-title":"Discov. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Benevolo Savelli, C., Bisio, M., Legato, L., Fasano, F., Santambrogio, E., Nicolosi, M., Morra, D., Boccomini, C., Freilone, R., and Botto, B. (2024). Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice. Cancers, 16.","DOI":"10.3390\/cancers16101830"},{"key":"ref_112","unstructured":"Schroers-Martin, J., Spinner, M., Merryman, R., Chang, C., Yeung, A., Silin, C., Powell, M., Armand, P., Shipp, M.A., and Advani, R.H. (2024). P127: Phase II Trial Evaluating the Anti-CD47 Antibody Magrolimab in Combination with Pembrolizumab in Patients with Relapsed\/Refractory Classic Hodgkin Lymphoma. Hemasphere, 8."},{"key":"ref_113","unstructured":"Study Details (2025, July 23). Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma. ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04788043."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2019004701","article-title":"A Phase 1b Study of AFM13 in Combination with Pembrolizumab in Patients with Relapsed or Refractory Hodgkin Lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e8102841","DOI":"10.1097\/01.HS9.0000967776.81028.41","article-title":"S216: CD47\/PD-L1 Bispecific Antibody (IBI322) in Anti-PD-1 or PD-L1 Treatment-Resistant Classical Hodgkin Lymphoma: A Phase I Study","volume":"7","author":"Zhang","year":"2023","journal-title":"Hemasphere"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"11753","DOI":"10.1182\/blood-2022-159524","article-title":"A Phase 1, First-in-Human, Dose-Escalation Study of MGD024, a CD123 x CD3 Bispecific Dart\u00ae Molecule, in Patients with Relapsed or Refractory CD123-Positive (+) Hematologic Malignancies","volume":"140","author":"Winer","year":"2022","journal-title":"Blood"},{"key":"ref_117","unstructured":"Study Details (2025, July 23). A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies. ClinicalTrials.Gov, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05362773?cond=Systemic%20mastocytosis%20OR%20%22SMCD%20-%20systemic%20mast%20cell%20disease%22%20OR%20%22%20systemic%20tissue%20mast%20cell%20disease%22&aggFilters=status:not%20rec&viewType=Table&rank=10."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"9055","DOI":"10.1200\/JCO.2021.39.15_suppl.9055","article-title":"SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGF-\u03b2, for Advanced NSCLC with EGFR Mutations: Data from a Multicenter Phase 1 Study","volume":"39","author":"Shi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_119","unstructured":"Study Details (2025, July 23). Phase I\/II Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-Cell Lymphomas. ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04407741."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1200\/JCO.2023.41.16_suppl.2507","article-title":"Phase I Study of the Bifunctional Anti-PD-L1\/TGF-\u0392RII Agent SHR-1701 Combined with SHR2554, an EZH2 Inhibitor, in Patients with Previously Treated Advanced Lymphoma and Solid Tumors","volume":"41","author":"Feng","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the Efficacy and Tolerability of PET-Guided BrECADD versus EBEACOPP in Advanced-Stage, Classical Hodgkin Lymphoma (HD21): A Randomised, Multicentre, Parallel, Open-Label, Phase 3 Trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e432420","DOI":"10.1200\/EDBK_432420","article-title":"Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making","volume":"44","author":"Kahn","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1182\/bloodadvances.2023012145","article-title":"Brentuximab Vedotin and Chemotherapy in Relapsed\/Refractory Hodgkin Lymphoma: A Propensity Score-Matched Analysis","volume":"8","author":"Driessen","year":"2024","journal-title":"Blood Adv."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"6630","DOI":"10.1182\/bloodadvances.2023010622","article-title":"Brentuximab Vedotin plus AVD for Hodgkin Lymphoma: Incidence and Management of Peripheral Neuropathy in a Multisite Cohort","volume":"7","author":"Bowers","year":"2023","journal-title":"Blood Adv."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/bloodadvances.2023011470","article-title":"Transient Responses and Significant Toxicities of Anti-CD30 CAR T Cells for CD30+ Lymphomas: Results of a Phase 1 Trial","volume":"8","author":"Brudno","year":"2024","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.2023022197","article-title":"Dissection of Single-Cell Landscapes for the Development of Chimeric Antigen Receptor T Cells in Hodgkin Lymphoma","volume":"145","author":"Gottschlich","year":"2025","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-Specific CAR NK Cells Expressing IL-15 for the Treatment of CD19-Negative B-Cell Malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41698-024-00595-w","article-title":"Redirecting NK Cells to the Lymph Nodes to Augment Their Lymphoma-Targeting Capacity","volume":"8","author":"Leijonhufvud","year":"2024","journal-title":"NPJ Precis. Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin Lymphoma: 2025 Update on Diagnosis, Risk-Stratification, and Management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am. J. Hematol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7508\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:22:24Z","timestamp":1760034144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/15\/7508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":131,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["ijms26157508"],"URL":"https:\/\/doi.org\/10.3390\/ijms26157508","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}